Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pieris Pharmaceuticals Inc (NQ: PIRS )

16.98 +0.21 (+1.25%)
Streaming Delayed Price Updated: 11:28 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pieris Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 Next >
Stocks Stunted Midday as Reopening Plays Weaken
The major indexes have pared most of their pre-market gains, giving way to a somewhat static afternoon. 
Via Talk Markets
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Pieris Pharmaceuticals (NASDAQ:PIRS) stock moved upwards by 43.23% to $2.65 during Tuesday's regular session. As of 12:30 EST, Pieris Pharmaceuticals's... 
Via Benzinga
What's Going On With Pieris Pharmaceuticals Stock Today?
Pieris Pharmaceuticals Inc (NASDAQ:PIRS) shares are tradin... 
Via Benzinga
Pieris Stock Surges on Development Pact with Genentech for Respiratory, Ophthalmology Settings
Pieris Pharmaceuticals Inc (NASDAQ: PIRS) has entered into a multi-program research collaboration and license agreement with Genentech, a unit of ... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers AnPac Bio-Medical Science (NASDAQ:ANPC) shares increased by 27.99% to $5.99 during Tuesday's pre-market session. The market value of their outstanding shares... 
Via Benzinga
Pieris Pharmaceuticals Announces Respiratory and Ophthalmology Collaboration with Genentech
- Pieris will receive $20 million as an upfront payment and is eligible to receive more than $1.4 billion in additional potential milestone payments plus royalties for commercialized programs -... 
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Pieris Pharmaceuticals to Present at the Jefferies 2021 Virtual Healthcare Conference
BOSTON, MA / ACCESSWIRE / May 20, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology... 
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Pieris Pharmaceuticals: Q1 Earnings Insights
Shares of Pieris Pharmaceuticals (NASDAQ:PIRS) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share increased 0.00% over the past... 
Via Benzinga
Pieris Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON MONDAY, MAY 17, 2021 AT 8:00 AM EDT - PRS-060/AZD1402 dosed to first patient in phase 2a study - Cinrebafusp alfa (PRS-343) phase 2 study expected to... 
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Earnings Scheduled For May 17, 2021
Companies Reporting Before The Bell • Hycroft Mining Holding (NASDAQ:HYMC) is estimated to report earnings for its first quarter. • U.S. Well Services (NASDAQ:... 
Via Benzinga
The Week Ahead In Biotech: Sanofi, Bristol-Myers Squibb Await FDA Decisions, Earnings News Flow Tapers Off
Biotech stocks had a volatile ride in the week ended May 14, with stocks moving lower for much of the week before coming back up strongly in the final session. Some of the weakness may be traced back... 
Via Talk Markets
Exposures Product Safety
The Week Ahead In Biotech: Sanofi, Bristol-Myers Squibb Await FDA Decisions, Earnings News Flow Tapers Off
Biotech stocks had a volatile ride in the week ended May 14, with stocks moving broadly lower for much of the week before coming back up strongly in the final session. Some of the... 
Via Benzinga
Exposures Product Safety
Earnings Preview: Pieris Pharmaceuticals
On Monday, May 17, Pieris Pharmaceuticals (NASDAQ:PIRS) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release... 
Via Benzinga
Pieris Pharmaceuticals to Host First Quarter 2021 Investor Call and Provide Corporate Update on May 17, 2021
BOSTON, MA / ACCESSWIRE / May 10, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology... 
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Regulatory
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
Pieris Pharmaceuticals and Boston Pharmaceuticals Enter into an Exclusive Worldwide Product License for PRS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific
- Pieris will receive $10 million upfront and be entitled to receive additional milestone payments and tiered royalties - Boston Pharmaceuticals will be primarily responsible for development of the... 
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Regulatory
55 Biggest Movers From Yesterday
Gainers Celcuity Inc. (NASDAQ: CELC) jumped 29.4% to settle at $27.94. Celcuity shares climbed 51% on Friday after the company announced a worldwide licensing agreement with... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers 180 Life Sciences (NASDAQ:ATNF) shares increased by 27.31% to $12.4 during Monday's regular session. Trading volume for 180 Life Sciences's stock is 29.3... 
Via Benzinga
42 Stocks Moving In Monday's Mid-Day Session
Gainers Wilhelmina International, Inc. (NASDAQ: WHLM) shares jumped 44.8% to $8.05 after the company's 13D filing showed that Modell's Sporting Goods had reported a stake... 
Via Benzinga
Pieris Pharmaceuticals Presents Updated Phase 1 Monotherapy Data for 4-1BB/HER2 Bispecific Cinrebafusp Alfa and Preclinical Data for 4-1BB/PD-L1 Bispecific PRS-344/S095012 at 2021 AACR Annual Meeting
- Additional, ongoing confirmed durable partial response and three additional patients with stable disease as best response at the highest dose cohort of cinrebafusp alfa - Durable anti-tumor activity... 
From Pieris Pharmaceuticals, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Regulatory
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.